DNAitech is transforming point-of-care diagnostics with a portable, patent-pending platform that delivers lab-grade results for both human and animal health in under an hour.

Founded by Dr Murray Broom, the company addresses the critical challenge of slow, costly, and often inaccurate diagnostic processes, which contribute to significant economic losses in livestock and the global rise of antimicrobial resistance.

DNAitech’s solution integrates LAMP-CRISPR molecular technology, enabling multiplexed testing for multiple pathogens at once, with high sensitivity and specificity. The system is compact, battery-powered, and connects to smartphones for seamless data management, making it accessible in remote and low-resource settings.

The diagnostics market opportunity is substantial, with the swine disease segment valued at US$3.66 billion and AMR diagnostics at US$4.6 billion, both set for strong growth.

DNAitech has validated its technology through field trials with Institut Pasteur de Dakar and support from the Gates Foundation, demonstrating robust performance in real-world conditions. The business model combines hardware sales with recurring revenue from consumable test kits.

Led by an experienced team and advisors, DNAitech is raising NZ$1 million in a bridge round to advance commercial validation and prepare for a seed raise in 2027.